TIRmed Pharma announced closing a funding round of SEK 5.4M.

TIRmed Pharma, a Stockholm, Sweden-based pharma startup, announced completing a funding round of SEK 5.4M ($630k).

The money was raised from a range of local prviate investors from Sweden, and included a SEK 2.9 million contribution made by Almi Invest.

TIRmed Pharma was founded in 2018 by CEO Anna-Lena Spetz following the discovery of the now patented compounds. The active molecule and mechanism of action stems are to incoporated in a new antiviral drug for respiratory infections. It is a nasal spray that blocks viruses, with the potential to treat flu, RS virus and Corona.